Patents by Inventor Tsunataro Kishida

Tsunataro Kishida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lactic acid bacteria with immunoregulating activities
    Patent number: 7501274
    Abstract: The invention provides novel lactic acid bacteria having immunoregulating activities and usable in food and drinks, medicaments, and other applications. Specifically, the invention provides novel lactic acid bacteria separated from “Shibazuke,” one kind of traditional Kyoto pickles, and having immunoregulating activities. The lactic acid bacteria of the present invention belong to Lactobacillus pentosus.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: March 10, 2009
    Assignee: Suntory Limited
    Inventors: Yuji Nonaka, Takayuki Izumo, Kaoru Akatani, Atsuko Kishi, Tsunataro Kishida
  • Lactic acid bacteria with immunoregualting activites
    Publication number: 20050266545
    Abstract: The invention provides novel lactic acid bacteria having immunoregulating activities and usable in food and drinks, medicaments, and other applications. Specifically, the invention provides novel lactic acid bacteria separated from “Shibazuke,” one kind of traditional Kyoto pickles, and having immunoregulating activities. The lactic acid bacteria of the present invention belong to Lactobacillus pentosus.
    Type: Application
    Filed: March 31, 2005
    Publication date: December 1, 2005
    Applicants: SUNTORY LIMITED, LOUIS PASTEUR CENTER FOR MEDICAL RESEARCH
    Inventors: Yuji Nonaka, Takayuki Izumo, Kaoru Akatani, Atsuko Kishi, Tsunataro Kishida
  • Method for treating cancer patients
    Patent number: 5846928
    Abstract: A new immunotherapy to cancer patients is provided. In the therapy, lymphocytes collected from a patient by leukopheresis are treated with interferon-.alpha. in vitro for a short period of term and then returned to the patient intravenously. According to the therapy, reduction in sensitivity of tumor cells to natural killer-cell lysis due to administration of interferon-.alpha. is eliminated, the activities of NK cell and 2-5AS and interferon-producing capacity can be enhanced, a large amount of lymphocytes can be activated directly in vitro with the dose of optimally adjusted to the patient, none of side effects are found, and any other potentiators and comodulaators, which may not be allowed to use in vivo, can be added to the lymphocytes and removed therefrom before returning to the patient.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: December 8, 1998
    Assignee: PasKen Products Co., Ltd.
    Inventor: Tsunataro Kishida
  • Method of measuring interferon acitivity
    Patent number: 5766864
    Abstract: A method of measuring the activity of interferon-.alpha., .beta. or .omega., which comprises bringing a sample containing interferon into contact with a cell and determining an induced protein is provided.
    Type: Grant
    Filed: November 1, 1995
    Date of Patent: June 16, 1998
    Assignee: Sumitomo Pharmaceuticals Company, Ltd.
    Inventors: Kazuko Uno, Tsunataro Kishida, Keiji Fujioka, Yoshihiro Takada, Takayuki Sato
  • Method of increasing interferon production in humans
    Patent number: 5662900
    Abstract: A composition containing powdered Lactobacillus brevis subsp. coagulans is used to enhance the immunological functions of a patient, particularly with respect to increasing interferon production, 2-5A synthetase activity and Natural Killer activity.
    Type: Grant
    Filed: June 19, 1996
    Date of Patent: September 2, 1997
    Assignees: Institut Pasteur De Kyoto, Shinwa Pharmaceutical Co., Ltd., Nitto Pharmaceutical Industries, Ltd.
    Inventor: Tsunataro Kishida
  • Lactobacillus used to enhance immunological functions
    Patent number: 5556785
    Abstract: A composition containing powdered Lactobacillus brevis subsp. coagulans is used to enhance the immunological functions of a patient, particularly with respect to increasing interferon production, 2-5A synthetase activity and Natural Killer activity.
    Type: Grant
    Filed: October 27, 1993
    Date of Patent: September 17, 1996
    Assignees: Institut Pasteur de Kyoto, Shinwa Pharmaceutical Co., Ltd., Nitto Pharmaceutical Industries Ltd.
    Inventor: Tsunataro Kishida